Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World April 9, 2014 Andy Extance	Sun set on Ranbaxy rescue India's Sun Pharma will acquire its compatriot Ranbaxy in a $3.2 billion all-share deal that will create the world's fourth largest generic drugs producer.
Chemistry World May 7, 2014 Phillip Broadwith	Insider trading allegations stall Sun -- Ranbaxy deal The merger deal that would create India's largest pharmaceutical company has been stalled by accusations of insider trading of shares in the lead-up to the takeover announcement.
Chemistry World April 22, 2015 Phillip Broadwith	Daiichi Sankyo steps out after Sun-Ranbaxy merger Japanese firm Daiichi Sankyo has sold off its entire stake in India's Sun Pharmaceuticals, following Sun's takeover of Indian rival Ranbaxy, in which Daiichi was the controlling shareholder.
Chemistry World November 21, 2014 Rebecca Trager	Ranbaxy sues over withdrawn US approvals Ranbaxy -- India's largest generics manufacturer -- has sued the US Food and Drug Administration after the agency withdrew tentative approval for the company to sell generic versions of two blockbuster drugs
Chemistry World June 13, 2008 Sarah Houlton	Daiichi Sankyo makes bid for Ranbaxy The combination of the two companies - one focused on research and the other predominantly on generics - bucks the trend for research-based companies selling off or spinning out their generics businesses.
Chemistry World May 23, 2013 Phillip Broadwith	$500m fine over generics fraud for Ranbaxy A long-running investigation by the US Department of Justice and Food and Drug Administration has ended with a $500 million fine for generic drugmaker Ranbaxy.
BusinessWeek February 27, 2006 Einhorn & Kripalani	In India, Selling Generics Used To Be So Easy Suddenly, Indian drugmakers Dr. Reddy's and Ranbaxy have a host of copycat rivals.
BusinessWeek April 18, 2005 Manjeet Kripalani	India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India.
BusinessWeek July 14, 2003 Einhorn & Kripalani	In India a Little Lab Work and Lots of Lawyers Ranbaxy, a maker of generic drugs, must win lawsuits to grow
Chemistry World July 28, 2008 Rebecca Trager	Ranbaxy troubles place FDA under fire Indian drug firm Ranbaxy is facing scrutiny by American federal agencies and lawmakers over allegations that the company falsified scientific evidence to gain US approval for its products.
Chemistry World August 21, 2015 Sa njay Kumar	Indian pharma under increased regulatory scrutiny A Europe-wide ban on hundreds of generic pharmaceutical formulations tested by Indian contract research firm GVK Biosciences comes into force today.
Chemistry World May 3, 2012 Akshat Rathi	Ranbaxy launches new anti-malarial Synriam It is the first recently developed antimalarial that is not based on artemisinin, one of the most effective treatments for malaria, which has begun to suffer from problems with resistance in recent years.
Chemistry World October 17, 2014 Dinsa Sachan	Indian manufacturers hit back over quality claims The Indian pharmaceutical industry has asked its government to sue authors of a study published by the US National Bureau of Economic Research in early September.
Chemistry World October 23, 2013 Sarah Houlton	Pharma manufacturing woes dog industry Many problems arise from quality control failures, according to Nicholson Price from Harvard Law School's Petrie-Flom center for health law policy, biotechnology and bioethics, this is not the only problem -- regulatory constraints can prevent process improvements being made.
Chemistry World May 26, 2015 Phillip Broadwith	Endo to buy Par as generics consolidation continues Irish-headquartered firm Endo Pharmaceuticals has agreed to buy private US firm Par Pharmaceuticals in a deal worth around $8 billion in a combination of cash, shares and assumed debt.
Chemistry World January 27, 2014 Phillip Broadwith	US blocks imports from fourth Ranbaxy plant The US Food and Drug Administration has banned Indian drugmaker Ranbaxy from importing active pharmaceutical ingredients produced at its plant at Toansa, India, into the US.
The Motley Fool September 18, 2008 Brian Orelli	Ranbaxy's Troubles Won't Help Competitors The FDA will block the importing of more than 30 drugs and ingredients until Ranbaxy's problems at two Indian manufacturing plants are resolved.
Chemistry World July 25, 2012	Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population.
Pharmaceutical Executive October 1, 2011 Amrita Ghaswalla	Changing the Dialogue No industry leader is more closely associated with the goal of seeding the globe with low-cost generics than Mumbai-based Cipla Chairman Y.K. Hamied.
The Motley Fool July 22, 2008 Brian Orelli	The Growth Doctor Is In Dr. Reddy's grows the top line, but it still has some work to do.
Chemistry World September 18, 2008 James Mitchell Crow	Ranbaxy hit by US drug ban The US Food and Drug Administration (FDA) has banned the import of more than 30 drugs made by Ranbaxy, India's largest drugmaker.
BusinessWeek January 12, 2004 Manjeet Kripalani	India: Big Pharma's New Promised Land? Drugmakers are heeding the siren call of its well-trained, cheap chemists.
BusinessWeek October 10, 2005 Manjeet Kripalani	India: A Quiet Shopping Spree So far, foreign companies being bought by Indian players are small - but that's likely to change
The Motley Fool April 12, 2011 Brian Orelli	Merck Joins the Low-Margin Party The American drugmaker announces that it is partnering with Sun Pharma to establish a joint venture to sell branded generics in emerging markets.
Pharmaceutical Executive September 1, 2008 Sarah Houlton	Doing More With Less In order to take a big step forward, GlaxoSmithKline looks to employ smaller licensing deals and business units.
Pharmaceutical Executive July 3, 2007	Thought Leader: Connected Markets, Rob Dhoble It used to be that pharma companies had one marketing strategy for the US and other developed nations, a second strategy for emerging countries, and a third, mostly focused around access, for the developing world. But in a global environment, that doesn't work.
Pharmaceutical Executive October 1, 2010	Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector.
The Motley Fool May 13, 2008 Brian Orelli	Is Merck Keeping Its Enemies Close? The drugmaker strikes a deal with an Indian generic company.
Chemistry World October 28, 2015 Phillip Broadwith	Job cuts at Daiichi, Perrigo and Cabot Three pharma firms -- Daiichi Sankyo, Perrigo and Allergan -- and specialty chemicals company Cabot are to cut thousands of jobs between them in restructuring efforts.
Chemistry World February 25, 2014 Sarah Houlton	Megamerger brings Actavis into R&D race Generic drug giant Actavis is to buy speciality pharmaceutical firm Forest Labs in a deal worth about $25 billion, bringing Actavis into the drug discovery business.
Pharmaceutical Executive January 1, 2012 Jill Wechsler	New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation.
The Motley Fool December 19, 2005 Stephen D. Simpson	Pfizer Wins, a Sector Rejoices The pharmaceutical dodges a bullet and investors find renewed enthusiasm for big-cap pharma.
The Motley Fool February 26, 2009 Brian Orelli	Ranbaxy Spoils It for Everyone The Food and Drug Administration claims that generic-drug maker Ranbaxy falsified data that it submitted to the agency. Other innocent drug companies may suffer from guilt by association.
Chemistry World February 16, 2015 Phillip Broadwith	Teva wins generic esomeprazole race The copycat version will be marketed by Ivax Pharmaceuticals, a subsidiary of Israeli generic behemoth Teva.
Chemistry World May 21, 2009 Matt Wilkinson	Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets.
Pharmaceutical Executive August 1, 2011 Ben Comer	Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever.
Chemistry World January 6, 2015 Sarah Houlton	Riding new waves Global annual spending on medicines is set to top $1 trillion for the first time in 2014, having ended 2013 just shy of that figure at $989 billion.
The Motley Fool June 26, 2006 Stephen D. Simpson	Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note.
Pharmaceutical Executive August 1, 2006 Patrick Clinton	From the Editor: Take Your Seat There's a lot to accomplish in the pharmaceutical industry. But considering what the industry has done in 25 years, it's not impossible.
The Motley Fool April 15, 2004 Phil Wohl	Sun Sets Over Microsoft With Microsoft and Sun making nice, which stock is a better buy? Sun's prospects are looking brighter than they have in a long time. Right now, the company looks to have greater upside than the Redmond giant.
The Motley Fool August 6, 2008 Linda Brewton	Partly Cloudy Days Ahead for Sun Microsystems After reporting fourth-quarter results that were mainly in line with Wall Street expectations, Sun Microsystems now predicts a slight decline in sales and negative earnings per share for its current quarter.
Pharmaceutical Executive September 1, 2008 Jill Wechsler	Foreign Affairs FDA missteps and global outsourcing are drawing Congressional scrutiny and prompting new oversight approaches.
JavaWorld January 2001 James Niccolai	Sun, Microsoft settle Java lawsuit Microsoft has agreed to pay Sun Microsystems $20 million as part of an agreement to settle a bitter, 3-year legal battle over its use of Sun's Java programming language...
The Motley Fool July 28, 2005 Tom Taulli	Is Sun Getting Eclipsed? Maybe the best strategy for Sun is just to give money back to its shareholders.
InternetNews January 24, 2008 Andy Patrizio	Sun Tops Estimates in Second Quarter Total sales for Sun Microsystems came in slightly higher than expected and profits almost doubled from the year-ago quarter.
The Motley Fool May 2, 2008 Anders Bylund	Sun's Cloudy Vision Sun Microsystems publishes a train wreck of a quarterly report.
Pharmaceutical Executive January 1, 2007 Glass & Poli	Forecast 2007: Connecting the Dots How do execs rank the issues facing the pharmaceutical industry? And what are the links they see between them? A new study reveals the industry's mental map of today's challenges.
Chemistry World August 20, 2012	Generic Actos Approved Three generics manufacturers - Mylan, Ranbaxy and Teva - have won US marketing approval for their generic versions of Actos diabetes tablets.
InternetNews May 8, 2009 Andy Patrizio	Sun Faces Suit Over Oracle Deal, Bribery Probe Three suits are filed to stop the Oracle takeover, while the company looks into possible overseas bribery incidents.
BusinessWeek July 31, 2006 Pete Engardio	Emerging Giants Multinationals from China, India, Brazil, Russia, and even Egypt are coming on strong. They're hungry - and want your customers. They're changing the global game.